Innovation in bone healing and tissue repair

26 May 16
Kuros Invites to the Annual Shareholders’ Meeting 2016
Schlieren (Zurich), Switzerland, May 26, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced that the Annual Shareholders’ Meeting 2016 will take place on Thursday, June 16, 2016 at 1 p.m. at the Com-pany’s offices in Schlieren/Zurich......READ MORE
26 Apr 16
Kuros Biosciences Reports Financial Results for 2015
Three extraordinary one-time factors lead to positive result for 2015 Debt-free balance sheet after mandatory conversion of bonds and settlement with convertible loan note holders ......READ MORE
20 Apr 16
Kuros receives milestone payment from Checkmate
Kuros Biosciences Ltd. (“Kuros” or the “Company”), has been informed by Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) that the first melanoma patient has been dosed in a Phase 1b clinical trial with CMP-001, formerly known as......READ MORE
08 Mar 16
Kuros Biosciences Ltd. appoints Chief Medical Officer
Kuros Biosciences Ltd. (“Kuros” or the “Company”), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect. Dr. Jamieson has spent over 25 years in......READ MORE
20 Jan 16
Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd. which is renamed Kuros Biosciences Ltd.
Kuros Biosciences Ltd. (SIX:KURN formerly CYTN) (“Kuros”) today announced the closing of the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd. Starting 20 January 2016 all......READ MORE
08 Jan 16
Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers
Cytos Biotechnology Ltd announced today that the Board of Directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as Chairman of the Board and Mr. Dominik Ellenrieder being appointed as the Vice Chairman of......READ MORE
06 Jan 16
Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd. approves all resolutions
Cytos Biotechnology Ltd announced today that its shareholders have approved all resolutions at today’s Extraordinary Shareholders’ Meeting with overwhelming majority. These resolutions, among other things, consist of an ordinary capital......READ MORE

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Sealants
    Surgical sealants
    KUR-023
  3. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News & Events

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Press releases

26 May 16
Kuros Invites to the Annual Shareholders’ Meeting 2016
Schlieren (Zurich), Switzerland, May 26, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced that the Annual Shareholders’ Meeting 2016 will take place on Thursday, June 16, 2016 at 1 p.m. at the Com-pany’s offices in Schlieren/Zurich......READ MORE
26 Apr 16
Kuros Biosciences Reports Financial Results for 2015
Three extraordinary one-time factors lead to positive result for 2015 Debt-free balance sheet after mandatory conversion of bonds and settlement with convertible loan note holders ......READ MORE
20 Apr 16
Kuros receives milestone payment from Checkmate
Kuros Biosciences Ltd. (“Kuros” or the “Company”), has been informed by Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) that the first melanoma patient has been dosed in a Phase 1b clinical trial with CMP-001, formerly known as......READ MORE
08 Mar 16
Kuros Biosciences Ltd. appoints Chief Medical Officer
Kuros Biosciences Ltd. (“Kuros” or the “Company”), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect. Dr. Jamieson has spent over 25 years in......READ MORE
20 Jan 16
Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd. which is renamed Kuros Biosciences Ltd.
Kuros Biosciences Ltd. (SIX:KURN formerly CYTN) (“Kuros”) today announced the closing of the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd. Starting 20 January 2016 all......READ MORE
08 Jan 16
Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers
Cytos Biotechnology Ltd announced today that the Board of Directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as Chairman of the Board and Mr. Dominik Ellenrieder being appointed as the Vice Chairman of......READ MORE
06 Jan 16
Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd. approves all resolutions
Cytos Biotechnology Ltd announced today that its shareholders have approved all resolutions at today’s Extraordinary Shareholders’ Meeting with overwhelming majority. These resolutions, among other things, consist of an ordinary capital......READ MORE